The efficacy and safety of Fexuprazan-based triple therapy for Helicobacter pylori eradicatio

Not Applicable

Recruiting

• Conditions: Neoplasms

• Registration Number: KCT0008525
• Lead Sponsor: Kangwon National University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 June 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Patients with atrophic gastritis, peptic ulcer disease, low grade MALT lymphoma, functional dyspepsia, idiopathic thrombotic purpura, gastric cancer or gastric adenoma diagnosed after endoscopic resection, family history of gastric cancer who tested positive for Helicobacter pylori using rapid urease test and urea breath test

Exclusion Criteria

1) Helicobacter pylori eradication in the past
2) Patients who must take PPI, antibiotcs or steroids for other purposes
3) Patients taking antiviral agents for AIDS
4) Patients taking P-CAB, PPI, H2 antagonist within 2 weeks prior to screening
5) Patients with acid secretion disorders, Zollinger–Ellison, and who have taken total or subtotal gastrectomy
6) patients with kidney and liver failure with AST, ALT, ALP, ?-GT, total bilirubin level above 2UNL, and BUN, creatinine above 1.5 UNL
7) patients with active gastric bleeding
8) patients with abnormal EKG such as prolonged QT
9) Patients who are unwilling to take contraceptive measures during clinical trial
10) Pregnancy or breastfeeding patients
11) Patients evaluated to be unfil for enrollment
12) patietns with centra nervous infection, hypokalemia, or hypomagnesemia

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
H. pylori eradication rate

Secondary Outcome Measures

Name	Time	Method
Eradication rate for clarithromycin resistant strains, and medication side effects